Methods of using 2-methoxyestradiol of high purity

Details Methods of using 2-methoxyestradiol of high purity Methods of using 2-methoxyestradiol of high purity

2007-06-26

2007-06-26

Badio, Barbara P. (Department: 1617)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

Reexamination Certificate

active

11235574

ABSTRACT:
2-methoxyestradiol having greater than 98% purity is obtained by synthetic or purification methods. This highly pure 2-methoxy estradiol, lacking estrogenic components, is particularly suitable for clinical use in humans. The purification methods of the invention involve the use of liquid-solid chromatography (LSC) to separate 2-ME2 from other compounds. The chromatographic media is preferably silica. The solvent system comprises a non-polar solvent, such as chloroform, and a polar solvent, such as methanol.

REFERENCES:
patent: 2584271 (1952-02-01), Huffman
patent: 2846453 (1958-08-01), Hoehn
patent: 3166577 (1965-01-01), Ringold et al.
patent: 3410879 (1968-11-01), Smith et al.
patent: 3470218 (1969-09-01), Farah
patent: 3492321 (1970-01-01), Crabbe
patent: 3496272 (1970-02-01), Kruger
patent: 3562260 (1971-02-01), De Ruggieri et al.
patent: 3956348 (1976-05-01), Hilscher
patent: 4172132 (1979-10-01), Draper et al.
patent: 4212864 (1980-07-01), Tax
patent: 4307086 (1981-12-01), Tax
patent: 4444767 (1984-04-01), Torelli et al.
patent: 4522758 (1985-06-01), Ward et al.
patent: 4552758 (1985-11-01), Murphy et al.
patent: 4634705 (1987-01-01), DeBernardis et al.
patent: 4743597 (1988-05-01), Javitt et al.
patent: 4808402 (1989-02-01), Leibovich et al.
patent: 4994443 (1991-02-01), Folkman et al.
patent: 5001116 (1991-03-01), Folkman et al.
patent: 5135919 (1992-08-01), Folkman et al.
patent: 5504074 (1996-04-01), D'Amato et al.
patent: 5521168 (1996-05-01), Clark
patent: 5621124 (1997-04-01), Seilz et al.
patent: 5629340 (1997-05-01), Kuwano et al.
patent: 5639725 (1997-06-01), O'Reilly et al.
patent: 5643900 (1997-07-01), Fotsis et al.
patent: 5646136 (1997-07-01), Petrow
patent: 5661143 (1997-08-01), D'Amato et al.
patent: 5716981 (1998-02-01), Hunter et al.
patent: 5733876 (1998-03-01), O'Reilly et al.
patent: 5763432 (1998-06-01), Tanabe et al.
patent: 5776704 (1998-07-01), O'Reilly et al.
patent: 5792845 (1998-08-01), O'Reilly et al.
patent: 5837682 (1998-11-01), O'Reilly
patent: 5854205 (1998-12-01), O'Reilly et al.
patent: 5854221 (1998-12-01), Cao et al.
patent: 5861372 (1999-01-01), Folkman et al.
patent: 5885795 (1999-03-01), O'Reilly et al.
patent: 5892069 (1999-04-01), D'Amato et al.
patent: 5958892 (1999-09-01), Mukhopadhyay et al.
patent: 6011023 (2000-01-01), Clark et al.
patent: 6011024 (2000-01-01), Reed
patent: 6046186 (2000-04-01), Tanabe et al.
patent: 6051726 (2000-04-01), Sachdeva et al.
patent: 6054598 (2000-04-01), Sachdeva et al.
patent: 6136992 (2000-10-01), Ram et al.
patent: 6200966 (2001-03-01), Stewart
patent: 6239123 (2001-05-01), Green et al.
patent: 6284789 (2001-09-01), LaLonde et al.
patent: 6399773 (2002-06-01), Liu et al.
patent: 6407086 (2002-06-01), Faarup et al.
patent: 6410029 (2002-06-01), Mukhopadhyay et al.
patent: 6514971 (2003-02-01), Thomas et al.
patent: 6528676 (2003-03-01), D'Amato et al.
patent: 6605622 (2003-08-01), Green et al.
patent: 6723858 (2004-04-01), D'Amato et al.
patent: 6730665 (2004-05-01), Maran et al.
patent: 6908910 (2005-06-01), D'Amato et al.
patent: 7087592 (2006-08-01), Agoston et al.
patent: 2002/0002294 (2002-01-01), D'Amato et al.
patent: 2002/0165212 (2002-11-01), D'Amato et al.
patent: 2003/0096800 (2003-05-01), D'Amato et al.
patent: 2003/0236408 (2003-12-01), D'Amato et al.
patent: 2004/0072813 (2004-04-01), D'Amato et al.
patent: 2004/0214807 (2004-10-01), D'Amato et al.
patent: 2005/0020555 (2005-01-01), D'Amato et al.
patent: 2005/0101573 (2005-05-01), Faarup et al.
patent: 2006/0116360 (2006-06-01), Fogler et al.
patent: 1907330 (1969-10-01), None
patent: 2 004 516 (1970-09-01), None
patent: 27 57 157 (1977-12-01), None
patent: 3625315 (1988-01-01), None
patent: 0166937 (1986-08-01), None
patent: 857080 (1960-12-01), None
patent: 857081 (1960-12-01), None
patent: 1570597 (1980-07-01), None
patent: 2252498 (1992-08-01), None
patent: 39-5480 (1939-04-01), None
patent: 41 000100 (1966-01-01), None
patent: 42-928 (1967-01-01), None
patent: 58-131978 (1983-08-01), None
patent: 62-135472 (1987-06-01), None
patent: 63090763 (1988-04-01), None
patent: 63-119500 (1988-05-01), None
patent: 04-046120 (1992-02-01), None
patent: 11-209322 (1999-08-01), None
patent: 1240038 (1996-10-01), None
patent: WO 87/02367 (1987-04-01), None
patent: WO 88/03151 (1988-05-01), None
patent: WO 88/08002 (1988-10-01), None
patent: WO 90/15816 (1990-12-01), None
patent: WO 93/03729 (1993-03-01), None
patent: WO 93/10805 (1993-06-01), None
patent: WO 93/19746 (1993-10-01), None
patent: WO 95/04535 (1995-02-01), None
patent: WO 98/32763 (1998-07-01), None
patent: WO 98/40398 (1998-09-01), None
patent: WO 99/01142 (1999-01-01), None
patent: WO 99/22728 (1999-05-01), None
patent: WO 99/33858 (1999-07-01), None
patent: WO 99/33859 (1999-07-01), None
patent: WO 99/35150 (1999-07-01), None
patent: WO 00/07576 (2000-02-01), None
patent: WO 00/10552 (2000-03-01), None
patent: WO 00/66095 (2000-11-01), None
patent: WO 00/68246 (2000-11-01), None
U.S. Appl. No. 11/118,852, filed Apr. 29, 2005.
U.S. Appl. No. 09/644,387, filed Aug. 23, 2000.
Lilopristone/(1-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxy-1-propenyl)estra-4,9-diene-3-one; AK 98734,Dictionary of Drugs(1990),Dict. of Steroids(1991),Dict. of Org. Cmpds(6th Ed) (1996),Dict of Pharm Agents (1997), 1990.
The Merck Index 11th Edition, (paragraphs 583-584) p. 88, 1989.
Research Plus Catalog, pp. 50-58, 1993.
News Article: Hoffman-La Roche Signs $70 Million Deal with Millenium on Genomics Technology,Genetic Engineering News, Apr. 15, 1994.
News Article: Advanced Drug Delivery Systems Peak Interest of Pharmaceutical & Biotech Firms,Genetic Engineering News, Apr. 15, 1994.
News Article: Nasal Spray for Treating Bleeding Disorders,Genetic Engineering News, Apr. 15, 1994.
Aboulwafa et al., Synthesis and evaluation for uterotrophic and antiimplantation activities of 2-substituted estradiol derivatives,Steroids, vol./Iss: 57, pp. 199-204, Apr. 1992.
Adams, E.F. et al., Steroidal regulation of oestradiol-17B dehydrogenase activity of the human breast cancer cell line MCF-7 (Chemical Abstracts Doc. No. 109:32325, 1988),Journal of Endocrinology, vol./Iss: 118 (1), pp. 149-154, Jul. 1988.
Aizu-Yokota et al., Natural Estrogens Induce Modulation of Microtubules in Chinese Hamster V79 Cells in Culture,Cancer Research, vol./Iss: 55, pp. 1863-1868, May 1, 1995.
Algire, G.H. et al., Vascular reactions of normal and malignant tumors in vivo. 1. Vascular reactions of mice to wounds and to normal and neoplastic transplants,Journal of the National Cancer Institute, vol./Iss: 6, pp. 73-85, Aug. 1945.
Aliev et al., 54929q Synthesis of cycloakyl derivatives of dihydric phenols and their ethers,Chemical Abstracts, vol./Iss: 72, p. 370, 1970.
Anstead et al., The Estradiol Pharmacophore: Ligand Structure-Estrogen Receptor Binding Affinity Relationships and a Model for the Receptor Binding Site,Steroids, vol./Iss: 62, pp. 268-303, 1997.
Arnoldi et al., Sweet Isovanillyl Derivatives: Synthesis and Structure-Taste Relationships of Conformationally Restricted Analogs (Abstract only),Journal of Agric. Food Chem., vol./Iss: 46(10), pp. 4002-4010, 1998.
Attalla et al., 2-Methoxyestradiol Arrests Cells in Mitosis without Depolymerizing Tubulin,Biochemical and Biophysical Research Communications, vol./Iss: 228, pp. 467-473, 1996.
Attalla et al., 2-Methoxyestradiol-Induced Phosphorylation of Bcl-2: Uncoupling from JNK/SAPK Activation (Abstract only),Biochemical and Biophysical Research Communications, vol./Iss: 247 (3), pp. 616-619, Jun. 29, 1998.
Audier et al., Orientation de la fragmentation en spectrometrie de masse par introduction de groupements fonctionnels. VII.—Etheylenecetals de ceto-2 steroides,Bulletin De La Societe Chimique De France, vol./Iss: 10, pp. 3088-3090, 1965.
Ayala et al., The Induction of Accelerated Thymic Programmed Cell Death During Polymicrobial Sepsis: Control by Corticosteroids but not Tumor Necrosis Factor (Abstract only),Shock, vol./Iss: 3 (4), pp. 259-267, Apr. 1995.
Banik et al., Orally Active Long-Acting Estrogen (AY-20,121) (3-(2-propynyloxy)-estra-1,3,5,(10)-triene-17.

Affiliated with

Also associated with

Rating

Methods of using 2-methoxyestradiol of high purity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of using 2-methoxyestradiol of high purity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using 2-methoxyestradiol of high purity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3846505